← Leaderboards
Taslim A Al-Hilal
University Of Texas El Paso
$2,170,745
Attributed
$2,170,745
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $918.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,170,745 · 3
By mechanism
R01$1,043,357 · 1
SC1$740,250 · 1
R21$387,138 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Genes”
- Mari Ostendorf · University Of Washington$51,931,230
- Suma Babu · Massachusetts General Hospital$28,791,731
- Sabrina Paganoni · Massachusetts General Hospital$28,791,731
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
Research focus
GenesReportingCancer PatientChemotherapyProteinsMalignant NeoplasmsTumorTumor ProgressionBlood VesselsCancer CellNeoplasm MetastasisOncogenesKdr GeneCancer TherapyAffectPathway InteractionsImmunosuppressionImmuneImmune Checkpoint InhibitorImmunotherapyBindingGeneticAttenuatedCancer Model
Grant awards (9)
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity$352,275
R01 · FY2025 · CA · contact PI
Priming pancreatic ductal adenocarcinoma using blood thinners to sensitize the efficacy of checkpoint immunotherapy$383,750
SC1 · FY2023 · GM · contact PI
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity$342,189
R01 · FY2023 · CA · contact PI
The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancer$173,854
R21 · FY2023 · CA · contact PI
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity$1
R01 · FY2023 · CA · contact PI
The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancer$1
R21 · FY2023 · CA · contact PI
Priming pancreatic ductal adenocarcinoma using blood thinners to sensitize the efficacy of checkpoint immunotherapy$356,500
SC1 · FY2022 · GM · contact PI
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity$348,892
R01 · FY2022 · CA · contact PI
The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancer$213,283
R21 · FY2022 · CA · contact PI